Antibody Chimerization

Antibody Chimerization

Chimeric antibodies are antibodies combining parental antibody variable regions with any acceptor constant region. Thanks to the domain organization of antibodies, chimerization is straightforward and does not alter antibody affinity or specificity. The combination of rodent variable domains with human constant domains is the most widespread, however, we can combine your variable domains with constant domains of diverse species.

Applications

  • Therapeutic : Antibody chimerization is a preliminary step before antibody humanization in order to associate biological function to parental antibody and to decrease its immunogenicity. Alternatively, chimeric antibodies can be employed for therapeutic purposes in particular diseases (e.g. for immunocompromised patients) or under certain conditions (variable domain with high GI).
  • Diagnostic : Chimeric antibodies are the best alternative to serum, calibrators and positive controls in diagnostics assays. They are particularly suitable as they can be produced in unlimited quantities and homogeneous (preservation of antibody specificity and affinity.

BIOTEM does not claim any intellectual properties nor any other rights on the developed antibodies.

  • Straightforward process
  • Donor or acceptor domains from species of your choice
  • Preserved parental affinity and specificity
  • Starting from your parental antibody or from scratch
  • Parental Antibody

    Development

    1. Parental Antibody Development

    Depending on the stage of your project, BIOTEM proposes to take care of :

    Alternatively, chimerization can be implemented from any parental antibody sequences

  • Chimerization

    Antibody

    2. Chimerization

    Chimeric Antibody Design :

    • cDNA optimization for expression in mammalian cells (CHO)
    • Constant domain selection (specie and isotype)
    • Synthesis of the sequences coding for the VH and VL variable domains
    • Cloning of the sequences coding for the VH and VL variable domains in two expression vectors
    • Sequencing and validation of the expression vectors

    Production (CHO cell Platform)

    • Pilote production and purification
    • Low endotoxin Conditions (< 10 EU/mg ; even < 1 EU/mg)
    • Serum free System
    • Custom construction (Isotype, Mutations, Fc-Fusion protein, bispecific antibody, Fab, etc.)

    Antibody Characterization

    • Reactivity by ELISA
    • Affinity Determination
    • Characterization of soluble aggregation (SEC-HPLC)
    • Characterization of thermo stability (DSC)
    • Non-exhaustive list
  • Large Scale

    Production

    3. Large Scale Production

    Large scale productions are available with our CHO cell Platform. (Learn more)

    • From milligram to several grams.
    • Low endotoxin Conditions (< 10 EU/mg ; even < 1 EU/mg)
    • Serum free System
    • Antibody Engineering
    • Quality Control (concentration, purity, affinity, aggregation, stability, etc.)

TO ACCESS THE DOCUMENT, FILL THE FORM

  • *Required fields
  • The information collected from this form is recorded and transmitted to the staff of our company responsible for processing your message. See our privacy policy
    You have a right of access, rectification and opposition to data concerning you, which you can exercise by visiting this page: . Contact form DPO